Design and synthesis of α‐conotoxin GID analogues as selective α4β2 nicotinic acetylcholine receptor antagonists

The α4β2 nicotinic acetylcholine receptor (nAChR) is an important target for currently approved smoking cessation therapeutics. However, the development of highly selective α4β2 nAChR antagonists remains a significant challenge. α‐Conotoxin GID is an antagonist of α4β2 nAChRs, though it is significantly more potent toward the α3β2 and α7 subtypes. With the goal of obtaining further insights into α‐conotoxin GID/nAChR interactions that could lead to the design of GID analogues with improved affinity for α4β2 nAChRs, we built a homology model of the GID/α4β2 complex using an X‐ray co‐crystal structure of an α‐conotoxin/acetylcholine binding protein (AChBP) complex. Several additional interactions that could potentially enhance the affinity of GID for α4β2 nAChRs were observed in our model, which led to the design and synthesis of 22 GID analogues. Seven analogues displayed inhibitory activity toward α4β2 nAChRs that was comparable to GID. Significantly, both GID[A10S] and GID[V13I] demonstrated moderately improved selectivity toward α4β2 over α3β2 when compared with GID, while GID[V18N] exhibited no measurable inhibitory activity for the α3β2 subtype, yet retained inhibitory activity for α4β2. In this regard, GID[V18N] is the most α4β2 nAChR selective α‐conotoxin analogue identified to date. © 2013 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 102: 78–87, 2014.

[1]  E. Nielsen,et al.  Crystal Structure of Lymnaea stagnalis AChBP Complexed with the Potent nAChR Antagonist DHβE Suggests a Unique Mode of Antagonism , 2012, PloS one.

[2]  P. Taylor,et al.  Crystal structure of a Cbtx–AChBP complex reveals essential interactions between snake α‐neurotoxins and nicotinic receptors , 2005, The EMBO journal.

[3]  Norelle L Daly,et al.  Structural studies of conotoxins , 2009, IUBMB life.

[4]  R. Lewis,et al.  Therapeutic potential of venom peptides , 2003, Nature Reviews Drug Discovery.

[5]  E. Levin,et al.  Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone , 1994, Clinical pharmacology and therapeutics.

[6]  D. Bertrand,et al.  Structural determinants of selective alpha-conotoxin binding to a nicotinic acetylcholine receptor homolog AChBP. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Michele Zoli,et al.  Structural and functional diversity of native brain neuronal nicotinic receptors. , 2009, Biochemical pharmacology.

[8]  D. Craik,et al.  Inhibition of Neuronal Nicotinic Acetylcholine Receptor Subtypes by α-Conotoxin GID and Analogues* , 2009, Journal of Biological Chemistry.

[9]  T. Liljefors,et al.  Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. , 2005, Journal of medicinal chemistry.

[10]  H. Grubmüller,et al.  Efficient Binding of 4/7 α-Conotoxins to Nicotinic α4β2 Receptors Is Prevented by Arg185 and Pro195 in the α4 Subunit , 2012, Molecular Pharmacology.

[11]  J. Changeux,et al.  Long-term effects of chronic nicotine exposure on brain nicotinic receptors , 2007, Proceedings of the National Academy of Sciences.

[12]  D. Yoshikami,et al.  α-Conotoxin GIC from Conus geographus, a Novel Peptide Antagonist of Nicotinic Acetylcholine Receptors* , 2002, The Journal of Biological Chemistry.

[13]  Miljanich Gp,et al.  Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. , 2004 .

[14]  Richard A Houghten,et al.  A Synthetic Combinatorial Strategy for Developing α-Conotoxin Analogs as Potent α7 Nicotinic Acetylcholine Receptor Antagonists* , 2009, The Journal of Biological Chemistry.

[15]  J. Lindstrom,et al.  Alternate Stoichiometries of α4β2 Nicotinic Acetylcholine Receptors , 2003 .

[16]  A. M. Phillips,et al.  Oxidative folding and preparation of α‐conotoxins for use in high‐throughput structure–activity relationship studies , 2013, Journal of peptide science : an official publication of the European Peptide Society.

[17]  T. Sixma,et al.  Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors , 2001, Nature.

[18]  L. Dwoskin,et al.  Nicotinic receptor-based therapeutics and candidates for smoking cessation. , 2009, Biochemical pharmacology.

[19]  F. Jessen,et al.  Smoking upregulates α4β2* nicotinic acetylcholine receptors in the human brain , 2008, Neuroscience Letters.

[20]  M. Damaj,et al.  Nicotine place preference in the mouse: influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists , 2006, Psychopharmacology.

[21]  P. Alewood,et al.  Conotoxins as research tools and drug leads. , 2005, Current protein & peptide science.

[22]  Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. , 1998 .

[23]  Sébastien Dutertre,et al.  Toxin insights into nicotinic acetylcholine receptors. , 2006, Biochemical pharmacology.

[24]  T. Sixma,et al.  Insight in nAChR subtype selectivity from AChBP crystal structures. , 2009, Biochemical pharmacology.

[25]  T. Sixma,et al.  Crystal Structure of Acetylcholine-binding Protein from Bulinus truncatus Reveals the Conserved Structural Scaffold and Sites of Variation in Nicotinic Acetylcholine Receptors* , 2005, Journal of Biological Chemistry.

[26]  D. Bertrand,et al.  Crystal structure of nicotinic acetylcholine receptor homolog AChBP in complex with an α-conotoxin PnIA variant , 2005, Nature Structural &Molecular Biology.

[27]  A. C. Collins,et al.  Null mutant analysis of responses to nicotine: deletion of beta2 nicotinic acetylcholine receptor subunit but not alpha7 subunit reduces sensitivity to nicotine-induced locomotor depression and hypothermia. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[28]  S. Woodward,et al.  Diversity of Conus neuropeptides. , 1990, Science.

[29]  J. Daly,et al.  Membrane potential fluorescence: A rapid and highly sensitive assay for nicotinic receptor channel function , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  José L. Medina-Franco,et al.  Scanning Structure-Activity Relationships with Structure-Activity Similarity and Related Maps: From Consensus Activity Cliffs to Selectivity Switches , 2012, J. Chem. Inf. Model..

[31]  K. Kellar,et al.  The Comparative Pharmacology and Up-Regulation of Rat Neuronal Nicotinic Receptor Subtype Binding Sites Stably Expressed in Transfected Mammalian Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[32]  Richard A Houghten,et al.  Discovery of novel antinociceptive α-conotoxin analogues from the direct in vivo screening of a synthetic mixture-based combinatorial library. , 2013, ACS combinatorial science.

[33]  JaneR . Taylor,et al.  β2-Subunit-containing nicotinic acetylcholine receptors are involved in nicotine-induced increases in conditioned reinforcement but not progressive ratio responding for food in C57BL/6 mice , 2006, Psychopharmacology.

[34]  Antoine Taly,et al.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system , 2009, Nature Reviews Drug Discovery.

[35]  L. Dwoskin,et al.  Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse , 2009, Neuropsychopharmacology.

[36]  K. Lingenhöhl,et al.  Coupling of human nicotinic acetylcholine receptors α7 to calcium channels in GH3 cells , 2005, Neuropharmacology.

[37]  D. Bertrand,et al.  Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. , 2007, Annual review of pharmacology and toxicology.

[38]  B. Olivera,et al.  Conus venoms: a rich source of novel ion channel-targeted peptides. , 2004, Physiological reviews.

[39]  G. Bulaj,et al.  Conus venoms - a rich source of peptide-based therapeutics. , 2008, Current pharmaceutical design.

[40]  D. Craik,et al.  Isolation, Structure, and Activity of GID, a Novel α4/7-Conotoxin with an Extended N-terminal Sequence* , 2003, The Journal of Biological Chemistry.

[41]  C. Schroeder,et al.  chi-Conopeptide pharmacophore development: toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain. , 2009, Journal of medicinal chemistry.

[42]  J. McIntosh,et al.  Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors , 2009, Acta Pharmacologica Sinica.

[43]  P. Taylor,et al.  Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations , 2005, The EMBO journal.

[44]  T. Liljefors,et al.  Rational design of alpha-conotoxin analogues targeting alpha7 nicotinic acetylcholine receptors: improved antagonistic activity by incorporation of proline derivatives. , 2009, The Journal of biological chemistry.

[45]  G. Koob,et al.  Blockade of Nicotine Self-Administration with Nicotinic Antagonists in Rats , 1999, Pharmacology Biochemistry and Behavior.

[46]  R. Niaura,et al.  Fresh from the pipeline: Varenicline , 2006 .

[47]  T. Sixma,et al.  AChBP-targeted α-conotoxin correlates distinct binding orientations with nAChR subtype selectivity , 2007, The EMBO Journal.